Bynfezia Pen Interactions
There are 156 drugs known to interact with Bynfezia Pen (octreotide), along with 7 disease interactions, and1 alcohol/food interaction. Of the total drug interactions, 6 are major, 142 are moderate, and8 are minor.
- View all 156 medications that may interact with Bynfezia Pen
- View Bynfezia Pen alcohol/food interactions (1)
- View Bynfezia Pen disease interactions (7)
Most frequently checked interactions
View interaction reports for Bynfezia Pen (octreotide) and the medicines listed below.
- Afinitor (everolimus)
- Cuprimine (penicillamine)
- Diacomit (stiripentol)
- Dibenzyline (phenoxybenzamine)
- ethinyl estradiol
- Etopophos (etoposide)
- Extavia (interferon beta-1b)
- Gonal-f RFF Redi-ject (follicle stimulating hormone)
- Haldol Decanoate (haloperidol)
- hyaluronidase
- ifosfamide
- Inderal (propranolol)
- Kalydeco (ivacaftor)
- lamivudine
- ledipasvir / sofosbuvir
- Ludiomil (maprotiline)
- mesna
- norethindrone
- Novantrone (mitoxantrone)
- Pegasys (peginterferon alfa-2a)
- PegIntron (peginterferon alfa-2b)
- pravastatin
- Proglycem (diazoxide)
- protriptyline
- Rebif Rebidose (interferon beta-1a)
- Recombinate (antihemophilic factor)
- Rescriptor (delavirdine)
- Rituxan Hycela (hyaluronidase / rituximab)
- sapropterin
- Somavert (pegvisomant)
Bynfezia Pen alcohol/food interactions
There is 1 alcohol/food interaction with Bynfezia Pen (octreotide).
Bynfezia Pen disease interactions
There are 7 disease interactions with Bynfezia Pen (octreotide) which include:
- renal dysfunction
- gallbladder/biliary dysfunction
- glucose intolerance
- heart disease
- hepatic impairment
- thyroid dysfunction
- vitamin B12 deficiency
More about Bynfezia Pen (octreotide)
- Bynfezia Pen consumer information
- Compare alternatives
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: somatostatin and somatostatin analogs
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.